ICP-915

ICP-915 is a highly potent, selective covalent small-molecule inhibitor targeting the G12C mutant form of Kirsten rat sarcoma (KRAS) viral oncogene, being developed by InnoCare Pharma for the treatment of solid tumors driven by KRAS G12C mutations.[1][2][3][7] As a KRAS G12C inhibitor, ICP-915 is designed to irreversibly bind the mutant cysteine residue in the switch II pocket of KRAS, locking the protein in an inactive GDP-bound state and thereby blocking downstream signaling through pathways such as RAF–MEK–ERK and PI3K–AKT that drive tumor cell proliferation and survival.[1][2][3][7] The agent is part of InnoCare’s early-stage oncology pipeline and is planned to be developed both as monotherapy and in rational combinations, particularly with the SHP2 inhibitor ICP-189, to overcome resistance mechanisms and deepen responses in various KRAS G12C–mutant solid tumors.[1][2][4][6][7][8][13]